leuprorelin implant

Action and Spectrum

Action and spectrum: 

Leuprorelin is a synthetic analog of gonadotrophin-releasing hormone (GnRH). It increased potency and resistance to proteolysis. It will work as a GnRH agonist which tightly binds to the GnRH receptor on anterior pituitary cells. 

Drug Interaction

Adverse Reaction

Frequency not defined 

Fatigue 

Pulmonary embolism 

Blood glucose disturbances 

Bone pain 

Injection site reactions 

Nausea 

Dysgeusia 

Hot flushes 

Visual disturbances 

Increased appetite 

Headache 

Night sweats 

Joint pain 

Mood changes 

Nocturia 

Vomiting 

Fever 

Black Box Warning

Black box warning  

None  

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Long QT syndrome 
• Children under 18 years 
• Orchiectomy 

Cautions 

• Tobacco smoking 
• Cerebral metastases 
• Epileptic disorder 
• Chronic alcoholism 
• Predisposition to seizures 

Pregnancy / Lactation

Pregnancy Warnings: 

Pregnancy category: N/A 

Lactation: Excretion of the drug into the human breast milk is unknown 

Pregnancy categories: 

Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester. 

Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women. 

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 

Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology: 

leuprolide acts as a pituitary GnRH receptor agonist which initiates the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in the anterior pituitary.  

This shift leads to decrease in LH and FSH levels. In males, this reduction results in decreased testosterone levels to castrate levels.  

Pharmacodynamics: 

Limited information is available.  

Pharmacokinetics: 

Limited information is available on ADME.  

Adminstartion

Administration: 

It is administered via abdominal subcutaneous injection i.e., injecting into the fatty tissue just beneath the skin in the abdominal area. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: leuprorelin implant 

Why do we use leuprorelin implant? 

Leuprorelin implant is used in the treatment of advanced prostate cancer. 

It also effective in breast cancer treatment specially in premenopausal women.